Liquid Biopsy

Liquid Biopsy Liquid biopsy is always with you in the battle with cancer.

🚀 Advances in Liquid Biopsy: Transforming Cancer Care from Exploration to Clinical PracticeTissue biopsies have long bee...
21/09/2026

🚀 Advances in Liquid Biopsy: Transforming Cancer Care from Exploration to Clinical Practice

Tissue biopsies have long been the diagnostic standard, but they are invasive procedures with procedural risks and may not represent genomic heterogeneity across all tumor lesions. In contrast, liquid biopsy offers a minimally invasive, blood-based approach for real-time monitoring of tumor evolution and therapy response.

Here are 5 core clinical applications powered by circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs):

🔹 1. Early Cancer Detection & Screening Ultra-sensitive ctDNA assays and DNA methylation signatures enable multi-cancer early detection (MCED) and targeted screening in high-risk populations.

🔹 2. Minimal Residual Disease (MRD) & Relapse Surveillance Serial blood testing allows for precise MRD characterization and can detect cancer recurrence months before standard radiological imaging.

🔹 3. Real-Time Treatment Response Monitoring Quantitative ctDNA and CTC tracking provide dynamic feedback on therapeutic efficacy and help differentiate true tumor progression from pseudo-progression during immunotherapy.

🔹 4. Profiling Resistance Mechanisms & Targets Sampling circulating tumor products from all lesions captures multi-site heterogeneity, revealing therapeutic targets and emerging resistance mechanisms when tissue is inaccessible.

🔹 5. Multi-Omics Integration Combining ctDNA with cellular biomarkers like CTCs and extracellular vesicles (EVs) offers a comprehensive picture of tumor biology and host response.

Translating these assays into routine patient care requires interventional clinical trials to prove clinical utility, alongside global assay harmonization and quality assurance standards.

👇 What are your thoughts on integrating liquid biopsy into routine clinical oncology? Let’s connect and discuss in the comments!



Source: Advances in liquid biopsy: From exploration to practical application, Volume 43, Issue 2P161-165, February 10, 2025

Not every ctDNA trial ends in a clean win. DYNAMIC-III is a good example of why that’s still useful to talk about.In sta...
19/09/2026

Not every ctDNA trial ends in a clean win. DYNAMIC-III is a good example of why that’s still useful to talk about.

In stage III colon cancer, using ctDNA to guide therapy after surgery cut chemotherapy exposure and hospitalizations substantially. But it didn’t clearly beat standard care on recurrence-free survival, and escalating treatment for ctDNA-positive patients didn’t improve outcomes either.

What DID hold up: ctDNA remains one of the strongest recurrence-risk markers we have. 3-year recurrence-free survival ranged from 23% to 77% across ctDNA burden quartiles, a striking gradient.

The open question isn’t whether ctDNA carries signal. It’s what to do once you have it.

Source: Tie J, Wang Y, Loree JM, et al. Nature Medicine, 2025.
https://www.nature.com/articles/s41591-025-04030-w

ClinicalTrials OncologyResearch

The FDA approved atezolizumab as adjuvant therapy for muscle-invasive bladder cancer patients found to be ctDNA-MRD-posi...
17/09/2026

The FDA approved atezolizumab as adjuvant therapy for muscle-invasive bladder cancer patients found to be ctDNA-MRD-positive after cystectomy — and approved Signatera CDx as the companion diagnostic that identifies them.

Patients who test negative continue serial monitoring rather than receiving the added therapy.

This is what “precision oncology” looks like in practice. Not a slogan on a slide — a specific blood test result changing what happens next for a specific patient.

Source: FDA, May 15, 2026
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-atezolizumab-adjuvant-treatment-muscle-invasive-bladder-cancer-patients-molecular

A 2026 review mapped 191 cancer biosensor studies. The bottleneck wasn’t sensitivity, it was something else entirely.A J...
03/09/2026

A 2026 review mapped 191 cancer biosensor studies. The bottleneck wasn’t sensitivity, it was something else entirely.
A July 2026 scoping review in Biosensors mapped 191 primary studies (2024-2026) on nano-carbon biointerfaces, carbon dots, carbon nanotubes, graphene derivatives, and hybrid composites used in cancer biosensing.

The finding worth sitting with: analytical sensitivity did not scale simply with how sophisticated the nanomaterial was. A 3D hybrid composite didn’t automatically outperform a simpler carbon dot sensor. Performance depended more on how well the surface chemistry matched the target biomarker and sample type than on nanomaterial complexity alone.

The real bottleneck isn’t detection performance in the lab, it’s the gap between analytical proof-of-concept and translational, clinically usable evidence. Most of these 191 studies never leave the benchtop.

This is the same gap the chitosan-graphene cDNA sensor from earlier this week is trying to close, it’s one of a small number of designs actually validated on patient blood, not just spiked buffer.

What do you think is the harder problem: building a more sensitive sensor, or getting an existing one to survive real clinical samples?

Biosensors

A sensor built partly from crab shells just detected circulating tumor DNA down to 10 femtomolar.We talk a lot about wha...
01/09/2026

A sensor built partly from crab shells just detected circulating tumor DNA down to 10 femtomolar.

We talk a lot about what liquid biopsy detects. This is about what the detection actually runs on.

A 2025/2026 study built a 3D nanofiber mesh from graphene oxide and chitosan, the marine-derived component, sourced from crustacean shell waste, to detect a specific cDNA methylation variant directly from patient blood.
The design works as a three-step signal chain:
O Capture: chitosan-graphene nanofibers form the physical scaffold
• Recognition: gold nanoparticle probes identify the specific cDNA target

• Amplification: an antibody-carbon nanotube complex boosts the signal enough to measure

Result: a reliable detection range of 50-10,000 fmol/L, with a limit of detection of 10 fmol/L, in clinical blood samples, not just a spiked buffer solution, which is where most biosensor papers stop.

Does knowing the sensor material change how you think about assay reliability? Or is that too far downstream to matter clinically? Drop your take below

Every liquid biopsy result depends on something almost nobody talks about: what the sensor is actually built from.We tal...
31/08/2026

Every liquid biopsy result depends on something almost nobody talks about: what the sensor is actually built from.
We talk endlessly about what liquid biopsy detects, cDNA, CTCs, exosomes. We rarely talk about what the detection surface is built from.

One of the more interesting answers right now: the ocean.

🌊Chitosan: from crustacean shell waste, the capture scaffold in emerging cDNA nanosensors

🌊Alginate: from brown algaex tunable, biodegradable nanocarrier chemistry

🌊Fucoidan: also from brown algae, emerging in biosensor and isolation platforms

They’re biocompatible, biodegradable, and sourced from what’s otherwise seafood-processing waste.

What these materials actually do inside a sensor, the 2026 data behind them, and why “what it’s made of” might matter as much as “what it detects.”

Materials science people, is sensor substrate chemistry something you’d want to see more of on a liquid biopsy page?

🩸Liquid biopsy has transformed cancer diagnostics, but biomarker detection remains a major challenge.Circulating tumor D...
18/08/2026

🩸Liquid biopsy has transformed cancer diagnostics, but biomarker detection remains a major challenge.

Circulating tumor DNA (ctDNA), exosomes, circulating tumor cells (CTCs), microRNAs, and proteins exist in extremely low concentrations in peripheral blood.

Traditional analytical techniques, including PCR and next-generation sequencing (NGS), offer high sensitivity, but they also present several limitations:
• High operational costs
• Complex sample preparation
• Long turnaround times
• Dependence on centralized laboratories

This is where marine-derived nanomaterials are attracting significant scientific attention.

Materials extracted from marine organisms, including chitosan, alginate, fucoidan, and marine-derived silica, possess unique physicochemical properties:
V High surface-area-to-volume ratios
V Superior biocompatibility
V Functional groups that enable biomolecular immobilization
VIEnhanced electrochemical activity

When integrated into biosensors, these materials can amplify signals and improve the detection of ultra-low-abundance biomarkers.

The ultimate goal isn’t simply to create more sensitive sensors.

It’s to detect disease earlier, when therapeutic interventions have the greatest impact.

Clinical question:
Could marine-derived biosensors eventually reduce our dependence on expensive molecular testing?

PrecisionMedicine ClinicalResearch

Liquid biopsy’s first decade proved the concept. This next one is about proving it at scale, in the clinic, for every pa...
12/08/2026

Liquid biopsy’s first decade proved the concept. This next one is about proving it at scale, in the clinic, for every patient who needs it.
A few places the field is pushing hardest right now: fragmentomics (reading DNA by shape, not just sequence), pairing blood signals with spatial maps of the tumor itself, exosomes carrying cargo cDNA can’t touch, and, maybe the real bottleneck, regulatory and reimbursement systems catching up to what the science can already do.
This September, EAR’s Liquid Biopsies 2026 conference brings the field together in Lyon to work through exactly this.
Expect this page covering it live.
What’s the biggest unlock liquid biopsy needs next?
Better sensitivity for early-stage disease
Clearer regulatory/reimbursement pathways
Larger prospective outcome trials
Lower cost, broader access
Vote in the comments and follow for the research shaping
what comes next.

Huge thanks to 2,505 of you.I’m genuinely grateful for this community, for choosing primary sources over hot takes, and ...
11/08/2026

Huge thanks to 2,505 of you.

I’m genuinely grateful for this community, for choosing primary sources over hot takes, and for showing up in the comments to ask thoughtful, important questions.

If this page has been useful, tag a colleague who’d want it in their feed.

Thank you for being here.

Multi-cancer early detection (MCED) is the most ambitious application of liquid biopsy, and the most scientifically dema...
04/08/2026

Multi-cancer early detection (MCED) is the most ambitious application of liquid biopsy, and the most scientifically demanding.

The core challenge, highlighted again in recent 2026 literature: at early stages, tumor fraction in blood is extremely low, and the signal has to be distinguished from:

🧬Clonal hematopoiesis (CH), age-related mutations from blood cells, not tumor, which can mimic a cancer signal

🧬Normal biological noise across a healthy population

🧬The reality that a “positive” result still requires a
tissue-of-origin prediction to be clinically actionable, a positive signal alone doesn’t tell a clinician where to look

Recent reviews summarizing the MCED landscape point to converging biomarker classes, cDNA methylation, fragmentomics, CTCs, microRNAs, and exosomal cargo, being combined into multi-analyte models, because no single analyte alone has shown adequate sensitivity for early-stage, asymptomatic disease across cancer types.

This is why MCED validation requires enormous prospective cohorts followed over years, not just retrospective case-control studies. The science is real; the population-level evidence is still catching up.

Clonal hematopoiesis (CH) is one of the single biggest confounders in cDNA testing. Many labs now sequence a matched white blood cell (buffy coat) sample alongside plasma specifically to filter out CH-derived variants before calling a mutation “tumor-derived.”

What would you need to see in the data before recommending MCED testing to an asymptomatic patient?

Address

Cambridge

Website

Alerts

Be the first to know and let us send you an email when Liquid Biopsy posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share

Category